Comparative Preclinical Pharmacokinetics and Bioavailability of Antidepressant GSB-106 Tablet Form

Area of Science:

• Pharmacology
• Drug Development
• Biochemistry

Background:

• Antidepressant drug development is crucial for mental health treatment.
• Understanding drug pharmacokinetics is essential for efficacy and safety.
• GSB-106 is a novel compound under investigation for antidepressant properties.

Purpose of the Study:

• To determine the pharmacokinetics of GSB-106 in rabbits.
• To assess the relative bioavailability of an oral tablet formulation of GSB-106 compared to the active pharmaceutical substance.
• To establish a basis for further clinical development of GSB-106.

Main Methods:

• Single oral administration of GSB-106 (pharmaceutical substance and tablet form) to rabbits.
• Blood plasma sampling at determined intervals post-administration.
• Quantification of GSB-106 concentrations using High-Performance Liquid Chromatography (HPLC) coupled with mass spectrometry (MS).

Main Results:

• GSB-106 concentrations in rabbit blood plasma were successfully measured.
• The relative bioavailability of the GSB-106 tablet formulation was calculated to be 160.79% ± 24.33%.
• This indicates enhanced absorption of the tablet form compared to the substance alone.

Conclusions:

• The oral tablet formulation of GSB-106 demonstrates favorable bioavailability in rabbits.
• The pharmacokinetic profile supports further investigation into GSB-106 as a potential oral antidepressant.
• HPLC-MS is a suitable method for quantifying GSB-106 in biological matrices.